Osilodrostat for the treatment of Cushing syndrome: an update
Osilodrostat is an effective and well-tolerated therapy that leads to significant reductions in cortisol secretion and improves metabolic, cardiovascular, and psychological outcomes in patients with CS. Real-world studies support its efficacy across different forms and severities of endogenous hypercortisolism.
Authors
- Przemysław Witek (ORCID: https://orcid.org/0000-0003-0202-9192)
- Lukasz Dzialach
Institutions
- Medical University of Warsaw (PL)
Publication Details
- Journal
- Expert Review of Endocrinology & Metabolism
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1080/17446651.2026.2615346
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00